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AbstrACt
Introduction Cryptococcal meningitis is responsible 
for around 15% of all HIV-related deaths globally. 
Conventional treatment courses with amphotericin B 
require prolonged hospitalisation and are associated with 
multiple toxicities and poor outcomes. A phase II study has 
shown that a single high dose of liposomal amphotericin 
may be comparable to standard treatment. We propose 
a phase III clinical endpoint trial comparing single, high-
dose liposomal amphotericin with the WHO recommended 
first-line treatment at six sites across five counties. An 
economic analysis is essential to support wide-scale 
implementation.
Methods and analysis Country-specific economic 
evaluation tools will be developed across the five country 
settings. Details of patient and household out-of-pocket 
expenses and any catastrophic healthcare expenditure 
incurred will be collected via interviews from trial patients. 
Health service patient costs and related household 
expenditure in both arms will be compared over the trial 
period in a probabilistic approach, using Monte Carlo 
bootstrapping methods. Costing information and number of 
life-years survived will be used as the input to a decision-
analytic model to assess the cost-effectiveness of a 
single, high-dose liposomal amphotericin to the standard 
treatment. In addition, these results will be compared with 
a historical cohort from another clinical trial.
Ethics and dissemination The AMBIsome Therapy 
Induction OptimisatioN (AMBITION) trial has been evaluated 
and approved by the London School of Hygiene and 
Tropical Medicine, University of Botswana, Malawi National 
Health Sciences, University of Cape Town, Mulago Hospital 
and Zimbabwe Medical Research Council research ethics 
committees. All participants will provide written informed 
consent or if lacking capacity will have consent provided 
strengths and limitations of this study
 ► This economic analysis will provide evidence to in-
form policy decisions about the use of a more ex-
pensive medication in cryptococcal meningitis (CM).
 ► This analysis will provide data that may justify initia-
tives to increase the availability of a more expensive 
medication in CM.
 ► This approach will enable the development and ap-
plication of country-level costing tools across five 
African country settings which can be reused for 
future studies and contribute to capacity building in 
the region.
 ► The study is taking place at six large referral hos-
pitals across five countries in East and Southern 
Africa and the results might not be representative 
or generalisable to remote rural areas or settings in 
other countries.
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by a proxy. The findings of this economic analysis, part of the AMBITION 
trial, will be disseminated through peer-reviewed publications and at 
international and country-level policy meetings.
trial registration ISRCTN 7250 9687; Pre-results.
IntroduCtIon   
Cryptococcal meningitis (CM) is a severe fungal infection 
of the brain which occurs in advanced HIV infection. It is 
estimated that there are roughly 220 000 cases of CM glob-
ally per year with 73% of these occurring in sub-Saharan 
Africa. Annual global deaths are estimated at 181 000 and 
CM is responsible for approximately 15% of all AIDS-re-
lated deaths.1 
The current recommended first-line treatment for CM 
is amphotericin B deoxycholate (AmBd). AmBd is asso-
ciated with multiple drug-induced toxicities including 
anaemia, impaired renal function, electrolyte abnor-
malities and infusion-related reactions which make it 
unsafe to administer in high doses. AmBd is also diffi-
cult to administer, requiring hospitalisation for 7 to 
14 days of intravenous infusions, depending on which 
oral antifungal it has been paired with. In addition, 
treatment outcomes are poor with acute mortality at 
10 weeks ranging from 30% to 55%.2 The use of a lipo-
somal form of amphotericin called Ambisome (here-
after referred to as L-AmB) is associated with reduced 
drug-induced toxicities when compared with conven-
tional AmBd.3 The long tissue half-life and effective 
penetration into the brain tissue of L-AmB has prompted 
research into the effectiveness of treatment with short 
courses of high-dose L-AmB.4 The AMBisome Therapy 
Induction OptimisatioN (AMBITION) phase II clinical 
trial conducted in Botswana and Tanzania found that a 
single, high dose of 10 mg/kg L-AmB was well tolerated 
and led to a non-inferior reduction in fungal burden in 
cerebrospinal fluid when compared with standard 14-day 
courses of 3 mg/kg L- AmB.5 This dosing strategy is now 
being taken to a clinical endpoint trial.
The phase III AMBITION trial is a phase III open-
label randomised control non-inferiority trial to compare 
single, high-dose L-AmB treatment to the WHO first-line 
recommended regimen of a 7-day course of AmBd-based 
treatment in avoiding all-cause mortality in HIV-associ-
ated CM (figure 1).6 7 Eligible patients will be randomised 
to receive either:
1. L-AmB 10  mg/kg day 1 given with 14  days of fluco-
nazole 1200  mg/day and flucytosine 100  mg/kg/day 
(single dose) or
2. Amphotericin B deoxycholate 1 mg/kg/day for 7 days 
given with 7 days of flucytosine 100 mg/kg/day fol-
lowed by 7 days of fluconazole 1200 mg/day (control 
arm).
After the 2-week induction phase, all patients will 
receive fluconazole 800 mg/day to 10 weeks and 200 mg/
day thereafter. Antiretroviral therapy (ART) will be 
commenced 4 to 6 weeks after initiation of antifungal 
therapy. The trial will enrol 850 patients across six sites 
in five countries in Africa: Gaborone, Botswana (90); 
Blantyre (230) and Lilongwe (110), Malawi; Cape Town, 
South Africa (80); Kampala, Uganda (110) and Harare, 
Zimbabwe (230). All participants will be invited to take 
part in the economic evaluation study.
Figure 1 Economic evaluation flow diagram: trial entry, randomisation, treatment and follow-up.
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The use of L-AmB has potential implications for both 
clinical outcomes and healthcare costs. The widespread 
availability of L-AmB has previously been limited by the 
high cost of therapy: currently, the internationally listed 
price is $85 per 50 mg vial compared with $8 per 50 mg vial 
of AmBd. The listed cost per patient of the medication for 
the single-dose arm in this trial will be $996 versus $132 
for the control arm. However, the impact of a potentially 
more clinically effective intervention that is associated 
with fewer drug-induced toxicities and a reduced length 
of hospital stay may offset this expense. An argument 
for widening access to L-AmB has been strengthened 
since, in September 2018, Gilead announced as part of 
the expanded access preferential pricing programme for 
visceral leishmaniasis to include CM. While the normal 
cost in other countries varies from US$80 to US$400, 
the drug will now be available for US$16.25 in 116 low/
middle-income countries.8 This could have a dramatic 
impact on mortality.9
We plan an economic analysis to estimate the cost 
consequences and the cost-effectiveness of short-course 
L-AmB treatment, compared with the control arm, in five 
individual country settings across sub-Saharan Africa. The 
findings will also be compared with a historical cohort 
from the recently completed Advancing Cryptococcal 
Meningitis Treatment for Africa (ACTA) trial. The ACTA 
trial recruited patients in Cameroon, Malawi, Tanzania 
and Zambia and compared treatment outcomes among 
individuals receiving one of five different treatment regi-
mens, including the control arm used in the AMBITION 
trial.10 The purpose of this comparison is to identify 
any change in costs over time and any gross variation in 
health service costs between the AMBITION and ACTA 
cohorts, and to enable comparison of the cost-effective-
ness of the short-course L-AmB with the other regimens 
tested in ACTA.11
The hypotheses are that the short-course treatment:
1. Will show a zero-net societal cost change or that there 
will be societal cost savings from the short L-AmB 
treatment and an equivalent or increased effective-
ness of the treatment reducing mortality over a patient 
lifetime.
2. Will be cost-effective in terms of life-years saved over 
a patient lifetime when compared with historical co-
horts who received different combination treatment 
regimens in a recently completed clinical trial.
These analyses will aim to provide the economic 
evidence to support wide-scale implementation of short-
course L-AmB treatment across sub-Saharan settings.
objECtIvEs
The main objective of the economic analysis is to assess 
the cost-effectiveness of single, high-dose L- AmB 
compared with the control arm treatment regimen for 
HIV-associated CM across the five country settings in six 
sites.
secondary objectives
 ► To assess the cost consequences from the societal and 
health service perspective of single, high-dose L-AmB 
compared with the control arm across the five country 
settings.
 ► To assess the total health service costs per patient at 
each country site.
 ► To assess out-of-pocket expenses incurred by patients 
and households at all trial sites.
 ► To assess the percentage of catastrophic household 
expenditure experienced by patients at each trial site.
 ► To compare the total societal costs per patient and 
cost-effectiveness of a single, high-dose L-AmB with 
historical cohorts that received different treatment 
regimens within the ACTA trial.
MEthods And AnAlysIs
study design
The study is a prospective economic evaluation from the 
societal perspective—including both health service and 
patient related perspectives—comparing the costs and 
effectiveness of the two interventions at each of the six trial 
sites across the five country settings. The two key compo-
nents of this study are the collection of data concerning 
personal expenditure on health and the development 
of country costing tools, which will be applied to data 
concerning health service costs collected within the trial.
household expenditure
To estimate the societal costs at the patient and household 
level, they or their representatives will be interviewed at 
two points in time: within the first 5 days of randomisa-
tion and at their final face-to-face follow-up at week 10. 
The questionnaires, based on those used in the ACTA 
trial and further developed for this study, are designed 
to estimate their personal healthcare expenditure in the 
4 weeks leading up to enrolment and during the trial. A 
summary of the questions included in the questionnaire 
are presented in box 1. In addition, the out-of-pocket 
healthcare expenditure by the individual and their 
household, loss of income incurred due to illness and 
loss of labour time of the patients themselves and their 
carers will be collected using methods adopted in trials of 
a similar nature.12
The interview questions will preferably be asked 
directly to the patient. If the patient is confused or has 
reduced consciousness due to CM, a relative or next-
of-kin may provide proxy consent for them to enrol in 
the trial. It is unlikely that this person will be fully aware 
of the patient’s financial situation, and in these cases, 
it may be necessary to wait for the patient to recover 
before asking them directly. In cases where patients 
have prolonged confusion or are felt to have a poor 
prognosis, these questions can be asked of the proxy. 
Data will be collected by study doctors and nurses and 
entered into the trial Electronic Data Capture (EDC) 
system: a uniform database to be used across all sites. An 
interview guide for those collecting data from patients 
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will ensure that nuances and country-specific idioms are 
acknowledged.
The above methods have been developed through an 
iterative process. Initially, the lead Health Economist, 
who led on the ACTA cost-effectiveness analysis, and 
members of the Trial Management Group developed 
the data collection tools and integrated these into the 
wider trial EDC. This was later refined following a 1-week 
meeting of health economists and study team members 
from across the AMBITION sites held in Blantyre, 
Malawi in November 2017. This provided the opportu-
nity for experts working in this field and individuals who 
will collect data from patients to improve these tools by 
collecting and entering data from fabricated patients. 
Feedback was then integrated into both the data collec-
tion methods and the EDC and shared for final approval 
across the AMBITION consortium until a consensus was 
reached.
Country-specific costing approaches
Presently, each site has differing levels of experience with 
conducting economic analyses and has varied access to 
validated country costing tools. As stated, the preparation 
of the trial included a 1-week workshop with at least two 
team members from each site to assess the face validity 
and completeness of the questionnaire, to practise elec-
tronic data entry of the completed questionnaire, carrying 
costing computations, and to increase the knowledge and 
understanding of economic evaluation. In each country, 
resource use data will be collected using an ingredi-
ents-based approach. The data on individual resource use 
will be collected from all participants onto case report 
forms. Overhead costs, including costs of admissions and 
laboratory tests, will be collated from the hospitals’ finan-
cial and utilisation documents.
Botswana Harvard AIDS Institute Partnership: Gaborone, Botswana
Botswana Harvard AIDS Institute Partnership will use 
a microcosting approach to estimate CM treatment in 
Botswana from a single health provider’s perspective, 
in this case, from the Ministry of Health and Wellness 
perspective. The total of related costs, that is, patient-spe-
cific treatment cost and ‘hotel costs’ to cover CM treat-
ment will be determined as per the 2016 Botswana HIV 
Treatment Guidelines.13 All costs of pharmaceuticals 
will be taken from the listed tender prices at the Central 
Medical Stores, which procure stock and distribute phar-
maceuticals and healthcare commodities to all govern-
ment healthcare facilities. This package will provide 
an estimate of ‘patient specific’ costs of uncomplicated 
CM. ‘Hotel costs’ will determine the necessary hospital, 
staffing, capital and infrastructure requirements as the 
patient is admitted over a 7-day period. Data will be 
obtained from Princess Marina Hospital, which is the 
biggest, and main referral hospital in Botswana. Staff 
salaries will be taken from the Government of Botswana 
salary scales for health professionals. By combining this 
treatment costing data with the meningitis burden data 
generated through a previously completed audit, we 
will also generate an estimate of the total current costs 
to the Botswana health service of treating CM. The data 
will complement the ‘Estimated resource needs for key 
health interventions offered under Botswana’s Essential 
Health Services Plan (2013–2018)’ that project the cost 
of all health programmes, including the treatment of CM, 
from 2013 to 2018 and will also be used as a reference 
for the next version of this document to be published in 
2019.14
Malawi Liverpool Wellcome Trust Clinical Research Centre: 
Blantyre, Malawi
Standardised national health costing data are not 
available in Malawi. An existing costing tool which was 
developed for an HIV testing study will be adapted.15 
Patient-related healthcare costs will be obtained from 
the Central Medical Stores Trust, the only supplier 
mandated to supply government health facilities in 
Malawi. Personnel costs will be refined by referencing 
the Malawi government salary structures and payroll 
and estimating the proportion of health personnel 
time taken in the clinical care of the patient, as well 
as allowance costs for patients working out of working 
hours. Programme-related costs will be adapted using 
the results from recent costing studies within the Queen 
Elizabeth Central Hospital.15
University of North Carolina Project: Lilongwe, Malawi
Most of costing data for Lilongwe will be obtained using 
the same methods as that outlined above for Blantyre. 
In addition, local programme-related costs will be esti-
mated and projected through a local costing study 
within the Kamuzu Central Hospital. This adaptation 
will be based on existing local costing data as part of 
the Driving Reduced AIDS-associated Meningo-enceph-
alitis study, which will be shared with the AMBITION 
consortium.
box 1 structure of the health economics questionnaire 
for the AMbIsome therapy Induction optimisation study
 ► Personal health expenditure including on consultations, medication, 
travel time and costs
 ► Relative and/or household health expenditure in relation to the pa-
tient’s condition
 ► The duration and severity of the illness episode
 ► Loss of productivity and time off work for both patient and relative/s
 ► Profession and educational attainment of patient
 ► Profession and educational attainment of the person who earns the 
highest income (if not the patient)
 ► Access to social security, welfare support and health insurance
 ► Household expenditure on food, utilities, rent and large purchases 
such as cars, furniture and electrical items to assess the socioeco-
nomic status of the household
 ► The need for temporary loans or the sale of assets to fund health-
care and other costs in relation to the illness episode
 ► The level of disability and care needs of the patient
 o
n
 15 April 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026288 on 1 April 2019. Downloaded from 
5Ponatshego PL, et al. BMJ Open 2019;9:e026288. doi:10.1136/bmjopen-2018-026288
Open access
University of Cape Town: Cape Town, South Africa
There are currently no costing tools for primary data 
collection for disease-specific costing of CM treatment 
in South Africa. A costing tool will be developed from 
validated disease-specific costing tools for the South 
African context.16 Costs from the health service (Depart-
ment of Health) perspective will be collected using the 
ingredients costing approach and captured in an Excel 
spreadsheet. The quantity of resources used to treat CM 
in each study arm will be estimated from the trial and 
patient records. Prices for these treatment-related ingre-
dients will be obtained from the various service providers 
within the Department of Health that are responsible for 
offering the products and services. Specific activities by 
staff will be identified and estimated through the review 
of routinely collected time sheets. Human resource costs 
as well as recurrent and capital costs will be allocated 
using hospital expenditure and financial records as well 
as records from the Provincial Department of Health. 
The average cost of each treatment component will be 
calculated by multiplying the quantity of resources used 
by the unit price. From this, we can calculate the cost per 
case of CM treated by multiplying the average cost by the 
number of times a particular cost has been incurred.
Infectious Diseases Institute: Kampala, Uganda
Though there is a high burden of CM in Uganda, the 
costs associated with treatment have not been formally 
outlined in a costing tool. Previous research describing 
the costs of treatment used informally gathered estimates 
for treatment and management of the disease based on 
reports from various sources including local pharmacies, 
laboratories and the Ugandan Ministry of Health.17 The 
Uganda team will create a systematic costing tool for CM. 
This tool will consider the costs of treatment as well as the 
costs borne by the patients being treated. The creation 
of this tool will involve input from the Ministry of Health 
as well as the major suppliers of medications. We will 
engage these organisations and other key stakeholders to 
ascertain the current costs of meningitis treatment and 
develop a costing tool which can be adjusted in the future 
should costs change.
University of Zimbabwe School of Health Sciences: Harare, 
Zimbabwe
Clinical cost data will be collected alongside the clinical 
trial using microcosting methodologies. The economic 
evaluation will be done from the societal perspec-
tive to enable the study to assess the overall household 
economic impact of CM and will enable us to determine 
the patient and provider unit costs. This study is powered 
enough to detect both country-specific clinical and 
economic differences. Direct patient level clinical activity 
data such as drugs, staff time, diagnostics, pathology and 
radiology will be collected alongside the trial and rele-
vant unit costs determined using the study protocol. In 
other cases, prices for drugs, diagnostic and radiology 
tests will be collected from the National Pharmaceutical 
Company of Zimbabwe and national reference diagnostic 
and radiology laboratories, and from consultations with 
experts. Indirect and overhead costs such as management 
and administration costs, utilities and other capital costs 
for in-patient days will be determined using data from 
Parirenyatwa Hospital, Harare financial records, the 
WHO Choice Database and from previous clinical trials 
that took place at the proposed site.18 19
data collection and data management
Data collected and validated using the EDC system will be 
stored in an electronic database that is protected using 
a scheme of authentication and encryption. Paper docu-
ments, such as clinical notes and administrative docu-
mentation, will be kept in a secure location and held for 
5 years after the end of the trial. During this period, all 
data should be accessible to the competent or equivalent 
authorities, the sponsor and other relevant parties with 
suitable notice. Security of electronic records and data is 
a significant concern. All components of the distributed 
data systems will use authentication and encryption to 
render subject identity and personal health information 
unusable, unreadable or indecipherable to unauthorised 
individuals. Full Drive Encryption will be implemented 
at the hardware layer of all devices storing protected 
health information. A three-factor scheme will be used 
to authenticate users through the hardware layer to the 
application layer where personal health information 
is available. The applications will have user profiles to 
control access to certain data and reports. The applica-
tion and database layers will use a combination of hashing 
and encryption for sensitive and personal data. Mobile 
devices and the staff operating them will not be equipped 
with the encryption keys to decrypt selected sensitive data 
fields.
Confidentiality
The trial will be conducted in compliance with the 
approved protocol, the Declaration of Helsinki 2008, 
the principles of Good Clinical Practice and applicable 
national regulations. We plan to follow the principles of 
the UK Data Protection Act regardless of the countries 
where the trial is being conducted. Consent forms will be 
stored under the supervision of each local primary inves-
tigator in a secured office and accessible to trial staff only. 
The database will not hold personal details as participants 
are identified by their study number throughout the trial.
data analysis
As outlined above, information on resource use and 
number of units used will be collected at patient level 
through the EDC, as part of the trial, and through addi-
tional separate country costing studies. To validate and 
refine the data collection process, an early analysis will 
take place at each site after 10 patients have completed 
the 10-week study follow-up period.
On closure of the study, full data analysis will 
commence. First, an empirical cost-consequence analysis 
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will take place, using empirical individual patient data on 
societal resource use and unit cost based on the results 
from the costing studies.20 Both societal and healthcare 
perspectives are chosen, and health service patient costs 
including household costs, treatment cost and hospitalisa-
tions in both arms will be compared over the trial period 
in a probabilistic approach, using Monte Carlo boot-
strapping methods. To handle the heterogeneity of the 
trial population in within trial evaluation, we will derive 
a benefit value for each patient from the observed costs 
and effects and then construct a regression model with 
treatment variable and collected explanatory variables. 
Next, the costing information and number of life-years’ 
survival will be used in a decision analytic model to assess 
the cost-effectiveness of the single, high-dose arm against 
the control arm and also against other combination treat-
ment regimens from the ACTA trial. A Markov model has 
been chosen as it allows to explicitly account for passage 
of time to calculate time dependent costs and life-years of 
the remaining life span. Results will be presented using 
incremental cost-effectiveness ratios and cost-effective-
ness acceptability curves generated by Monte Carlo boot-
strapping methods. This approach avoids the stochastic 
fallacy and will determine if a single, high-dose L-AmB 
will be as or even more cost-effective compared with the 
current WHO recommended first-line treatment. An 
existing model will be adapted based on Jarvis et al, using 
the treatment submodel (figure 2).21 The Markov model 
has a monthly cycle length, running the model for 12 
cycles to calculate annual costs and annual life-years. We 
will supplement the model to be able to extrapolate data 
beyond the period of observed follow-up. The Markov 
modelling framework also allows for the synthesis of data 
from secondary sources, like mortality risk from other 
causes and excess mortality risks.17 It also allows for prob-
abilistic sensitivity analyses. We are going to use non-para-
metric bootstrapping to assess uncertainties, and both 
deterministic and probabilistic sensitivity analyses to 
examine the impact of all relevant parameters on the 
incremental cost-effectiveness ratio. The other country 
teams will be able to use an adapted model to enter their 
country-specific data and costing information as well as 
estimated survival figures, while using the pooled effec-
tiveness information. In this way, each country will arrive 
at valid country-specific economic estimates.
We will follow the Consolidated Health Economic 
Evaluation Reporting Standards appraisal guidelines on 
economic evaluation.22 As our study is an equivalence 
study using empirical data in a model-based analysis, 
these guidelines we will also include good modelling 
practice approaches.23
We anticipate the development of five different coun-
try-specific costing tools for CM which can be used to 
compose two five-country manuscripts concerning the 
cost consequence of CM across sites as well as the cost-ef-
fectiveness of the intervention across sites. In addition, 
individual country-level publications will be allowed, using 
the whole five-country trial database, complemented with 
local, more detailed country-level costing studies.
We intend to use these findings to provide an economic 
argument for the adoption of single, high-dose L-AmB in 
low/middle-income countries and to help influence guide-
lines and policy. Another important component of this 
study is capacity building across the African sites through 
the delivery of a health economics course and the ongoing 
mentoring of individuals and teams at each of the sites.
Patient and public involvement
For the primary AMBITION clinical trial, a number of 
the sites have well-developed community groups and are 
experienced in engaging local communities when under-
taking such studies. These groups were consulted prior 
to trial implementation, and they will be consulted regu-
larly during trial conduct. To engage the wider commu-
nity, we will work with community groups, HIV patient 
groups and local ministries of health to provide infor-
mation about the trial, disseminate the results and to 
develop health education materials aimed at dispelling 
the current beliefs around meningitis, and encouraging 
early care-seeking.
dIsCussIon And ConClusIon
This phase III clinical endpoint trial comparing single, 
high-dose liposomal amphotericin to the control arm 
treatment at six sites across five counties will provide 
valuable information on the comparative effectiveness 
with existing and other proposed strategies. This will 
be based on the effectiveness of simplified treatment 
strategies as well on the possibly increased safety. The 
proposed economic analysis of the equivalence trial for 
the Malawi situation will allow for a realistic compar-
ison with settings where there is very limited coverage of 
appropriate treatment of CM in people with HIV. The 
estimates from other trial settings will help to docu-
ment the generalisability of our findings. The economic 
information will be essential in the support of wide-
scale implementation strategies and the formulation 
and testing of alternative delivery modes in all compa-
rable sub-Saharan setting.
A clinically effective and safer treatment for CM in 
sub-Saharan Africa could have a dramatic impact on 
HIV-associated mortality in the region. This economic 
Figure 2 Simplified Markov model structure to evaluate the 
cryptococcal meningitis (CM) treatment.21
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analysis is essential to help justify any policy change 
towards increasing the availability of more expensive 
medication if it is proven to be cost-effective. This 
process will enable the development of country-specific 
costing tools across five African sites, which can be used 
for future studies and will build capacity in the region.
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